VYNE-Yarrow Merger Closes, $200M Financing Secured, Dosing Begins in Pivotal Graves' Disease Trial
VYNE is trading near its 52-week low of $14.025 (97% below the low) on elevated volume (3.9× avg).
Summary
The reverse merger between VYNE Therapeutics and Yarrow Bioscience has closed, creating a combined company focused on autoimmune thyroid diseases. The deal includes $200 million in private financings, extending the cash runway into 2028. Shares will trade under the new ticker YARW starting July 28. Critically, dosing has begun in a Phase 2a/2b trial of YB-101, a potential first-in-class anti-TSHR antibody for Graves' disease and thyroid eye disease, with Phase 2a data expected in the second half of 2027. This follows the July 18 stockholder approval and the July 21 reverse split and dividend announcements. The trial initiation and financing closure remove key uncertainties, positioning the company with multiple clinical catalysts and a strengthened balance sheet.
At the time of this announcement, VYNE was trading at $0.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21.9M. The 52-week trading range was $14.03 to $79.75. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.